Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 10/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 5/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.37 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.37 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.37 |
| ▸ | TGM2 | P21980 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14950517 | 0.87 | HTR6 (0.52) | HTR6GPR119TGFBR1 | |
| SCHEMBL4478387 | 0.86 | HTR6 (0.51) | HTR6GPR119TGFBR1NR1H2SMARCA2 | |
| SCHEMBL4476410 | 0.83 | ALDH1A1 (0.48) | HTR6TGFBR1 | |
| SCHEMBL4496217 | 0.80 | HTR6 (0.50) | HTR6GPR119TGFBR1NR1H2 | |
| SCHEMBL4489616 | 0.78 | HTR6 (0.60) | HTR6TGFBR1 | |
| SCHEMBL4477985 | 0.71 | HTR6 (0.59) | HTR6 | |
| SCHEMBL21198677 | 0.71 | ADRB1 (0.52) | — | |
| SCHEMBL5366208 | 0.70 | NAMPT (0.47) | GPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL13892446 | 0.70 | HTR6 (0.66) | HTR6GPR119TGFBR1 | |
| SCHEMBL4488704 | 0.69 | HTR6 (0.74) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123251-A1 | BENZOXAZINE DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC (US) | 2013-05-16 | — | — | US | disclosed |
| US-8377931-B2 | Benzoxazine derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2013-02-19 | — | — | US | disclosed |
| US-20090325950-A1 | Benzoxazine derivatives and uses thereof | ROCHE PALO ALTO LLC | 2009-12-31 | — | — | US | disclosed |
| EP-1506179-B1 | BENZOXAZINE DERIVATIVES AS 5-HT6 MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2006-01-25 | — | — | EP | disclosed |
| US-20050130962-A1 | Benzoxazine derivatives and uses thereof | BERGER JACOB (US) | 2005-06-16 | — | — | US | disclosed |
| US-6867204-B2 | Benzoxazine derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2005-03-15 | — | — | US | disclosed |
| EP-1506179-A1 | BENZOXAZINE DERIVATIVES AS 5-HT6 MODULATORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-16 | — | — | EP | disclosed |
| US-20030232825-A1 | Benzoxazine derivatives and uses thereof | ROCHE PALO ALTO LLC | 2003-12-18 | — | — | US | disclosed |
| WO-2003095434-A1 | BENZOXAZINE DERIVATIVES AS 5-HT6 MODULATORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325950-A1 | Benzoxazine derivatives and uses thereof | F12, CYP4X1, CYP3A5 | HTR6 2321/4885GPR119 697/4885TGFBR1 1547/4885 |
| US-20050130962-A1 | Benzoxazine derivatives and uses thereof | F12, HAX1, CYP4X1 | HTR6 2220/4885GPR119 713/4885TGFBR1 1502/4885 |
| US-20030232825-A1 | Benzoxazine derivatives and uses thereof | CYP3A5, CYP4X1, XDH | HTR6 1363/4885GPR119 1482/4885TGFBR1 2094/4885 |
| US-20130123251-A1 | BENZOXAZINE DERIVATIVES AND USES THEREOF | F12, CYP4X1, CYP3A5 | HTR6 2321/4885GPR119 697/4885TGFBR1 1547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.